Geoffrey L Uy on Muck Rack

Geoffrey L Uy

As seen in: Nature, The Lancet, OncLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Geoffrey L

Contact Geoffrey L, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database

|
By Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Tulika Gupta, Jessica M. Stempel, Najla Al Ali, Amy E. DeZern, Mikkael Sekeres, Geoffrey L Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew Brunner, Christine McMahon, Rory M. Shallis, Joshua F. Zeidner, Michael Savona, Constantine N Logothetis, Aram Bidikian, Gail J. Roboz, Benjamin Rolles, Eunice Wang, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David A Sallman, Anoop K. Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, María Díez-Campelo, David Valcárcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Maximilian Stahl, Rami S. Komrokji, Amer M Zeidan, Hayley Hawkins, Namrata Sonia Chandhok, Ted M. Getz, Amyah C. Harris, Jaclynn Campos
| Nature Verified
Abstract Monotherapy with hypomethylating agents (HMA) remains the standard of care for patients with higher-risk myelodysplastic neoplasms (HR-MDS). Recently, the randomized phase III VERONA study evaluating azacitidine plus venetoclax (VEN) versus azacitidine plus placebo in newly diagnosed HR-MDS showed no difference in overall survival (OS) between the two arms. However, whether the addition of VEN to HMA improves outcomes among subsets of patients with HR-MDS remains debated.
Open in Who Shared Issue with article?

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia

|
By Darren Lee, Deedra Nicolet, Krzysztof Mrózek, Mark J Routbort, Keyur Patel, Christopher Walker, Jill Hamilton Buss, Andrew Stiff, Courtney DiNardo, Tapan M Kadia, Farhad Ravandi, Andrew Carroll Verified, Jonathan E. Kolitz, Bayard Powell, William Blum, Maria R. Baer, Guido Marcucci, Geoffrey L Uy, Wendy Stock, Richard Stone Verified, L. Jeffrey Medeiros, John Byrd, James Blachly, Robert L. Bowman, Jeffrey W. Tyner, Sanam Loghavi, Ann-Kathrin Eisfeld, Linde Miles, Yazan Abu-Shihab, Kate Plas, Andrea Laganson
| Nature Verified
Open in Who Shared Issue with article?

Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies - Leukemia

|
By Shelley Orwick, Thomas Gregory, Kennedy Coleman, John Byrd, Wendy Stock, Geoffrey L Uy, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Sharyn D. Baker, Nadeen Anabtawi
| Nature Verified
Abstract The FLT3 gene frequently undergoes mutations in acute myeloid leukemia (AML), with internal tandem duplications (ITD) and tyrosine kinase domain (TKD) point mutations (PMs) being most common. Recently, PMs and deletions in the FLT3 juxtamembrane domain (JMD) have been identified, but their biological and clinical significance remains poorly understood. We analyzed 1660 patients with de novo AML and found FLT3-JMD mutations, mostly PMs, in 2% of the patients.
Open in Who Shared Issue with article?
See all 8 licensed articles (9 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified